Background Sickle-cell anaemia is associated with substantial morbidity from acute complications and organ dysfunction beginning in the fi rst year of life. Hydroxycarbamide substantially reduces episodes of pain and acute chest syndrome, admissions to hospital, and transfusions in adults with sickle-cell anaemia. We assessed the eff ect of hydroxycarbamide therapy on organ dysfunction and clinical complications, and examined laboratory fi ndings and toxic eff ects.
Introduction
Sickle-cell anaemia is characterised by haemoglobin polymerisation that results in sickle-shaped red blood cells, vaso-occlusion, haemolytic anaemia, and vasculoendothelial dysfunction, causing pain, organ injury, and early mortality. Clinical symptoms begin in the fi rst year of life, with a physiological decline in fetal haemoglobin concentration. Higher concentrations of fetal haemo globin are associated with fewer pain crises 1 and improved survival. 2 Hydroxycarbamide is an anti neoplastic drug that inhibits ribonucleotide reductase, increases fetal haemoglobin concentration in red blood cells, and has other potentially benefi cial eff ects, including improved nitric oxide metabolism, reduced red cell-endothelial interaction, and decreased erythrocyte density. 3 15 years ago the double-blind placebo-controlled Multi-Center Study of Hydroxyurea (MSH) in adults with severe sickle-cell anaemia showed that hydroxycarbamide substantially reduced episodes of pain and acute chest syndrome, admissions to hospital, and transfusions. 4 Subsequently, smaller studies have shown similar benefi ts and few toxic eff ects in schoolage children and adolescents. 5 In 2000, the US National Heart, Lung, and Blood Institute (NHLBI) awarded a competitive contract to test in a clinical trial whether hydroxycarbamide given to infants with sickle-cell anaemia for 2 years slows or prevents organ damage. In a pilot trial (HUSOFT), 6 very young children with sickle-cell anaemia tolerated a liquid hydroxycarbamide formulation (20 mg/kg per day), and had improved blood counts and fetal haemoglobin concentrations compared with predicted age-specifi c levels. 6 After 2 years, splenic radionuclide uptake was absent in only 47% of children, although 80% absence was predicted, leading to the choice of splenic function as a primary endpoint for the Pediatric Hydroxyurea in Sickle Cell Anemia (BABY HUG) trial. Because glomerular fi ltration rate (GFR) is abnormally increased early in life in children with sickle-cell anaemia, and can lead to progressive renal dysfunction, 7 we also assessed the eff ect of hydroxycarbamide on GFR as a primary endpoint.
We designed the BABY HUG trial to determine whether hydroxycarbamide safely prevents early damage to the spleen and kidneys in infants with sickle-cell anaemia. We also aimed to assess the eff ect of hydroxycarbamide on adverse clinical events, blood counts, additional aspects of organ function, and toxic eff ects. 8 
Methods

Patients
Participants aged 9-18 months were recruited between October, 2003, and September, 2007, at 13 trial centres in the USA. After written informed consent was obtained from their parents or guardians, potential study participants were assessed to establish eligibility and baseline status. An ombudsman was present at each site to promote understanding of the risks and demands of study participation. An unmasked so-called primary endpoint person monitored laboratory values and assisted in clinical management, and a feasibility and safety pilot study was done to assess toxicity in the fi rst 40 participants. 8 Initial assessments were repeated at study exit.
Eligible participants had HbSS or Sβ⁰thalassaemia, and were enrolled irrespective of clinical severity. All participants received standard age-appropriate care for sickle-cell anaemia, including penicillin prophylaxis, pneumococcal immunisation, and parental education.
Splenic sequestration
Increase in palpable spleen size by 2 cm or more below the costal margin from the last examination, accompanied by a decrease in haemoglobin of 20 g/L or more, or 20% or more from steady-state values. Participants were excluded for transfusion within 2 months; height, weight, or head circumference less than the fi fth percentile; mental developmental index (MDI) less than 70; or abnormal transcranial doppler ultrasound (TCD) velocity. 8 Ethics approval was obtained from a National Institutes of Health Protocol Review Committee and from each local centre's institutional review board.
Randomisation and masking
Participants were randomly assigned to either hydroxycarbamide (20 mg/kg per day) or placebo for 2 years, in a 1:1 ratio. 8 The randomisation sequence was pre-decided by a randomisation schedule developed for each clinical site by the medical coordinating centre. Double-blind randomisation was done with an automated telephone response system and the use of a random three digit kit number for each enrolled participant. The kit number, which was linked to the assignment sequence, was used by the drug distribution centre to ship the appropriate study drug to the clinical site pharmacy. Hydroxycarbamide and placebo powders had the same appearance and packaging and the liquid formulations had the same appearance and taste. Hydroxyurea and placebo were distributed to clinical centres in encoded kits. Local pharmacists reconstituted powder with syrup and water to a concentration of 100 mg/mL, 9 and dispensed a 35-day supply. As in the HUSOFT trial, 6 there was no dose escalation. Participants, caregivers, and medical coordinating centre staff were masked to treatment allocation.
Procedures
Masked readings of splenic uptake on ⁹⁹ m Tc-sulphur colloid liver-spleen scans were categorised qualitatively as normal, decreased (but present), or absent. We proposed that a decline in splenic uptake (from normal to decreased or absent, or from decreased to absent) would occur 50% less frequently in the hydroxycarbamide group than in the placebo group. GFR with ⁹⁹ endpoint was discontinued in May, 2009, because the monitoring board decided that further data gathering would be statistically futile. Secondary measures of splenic function were the quantitative ratio of nuclear decay counts in the spleen and liver, the proportion of red blood cells containing pits (small vacuoles normally removed by the spleen), and the proportion of mature red blood cells containing Howell-Jolly bodies. 11 Secondary measures of renal function were serum creatinine and cystatin C concentrations, urinalysis, and urine osmolality after limited fasting. 12 Investigations of the brain, lungs, hepatobiliary system, and growth and development were included as secondary endpoints or indices of toxicity; growth curves derived from Cooperative Study of Sickle Cell Disease (CSSCD) data were used to monitor height, weight, and head circumference. Neuro developmental assessment (Bayley Developmental and Vineland Adaptive Behavior Scales) and neurological examinations were done every 6-12 months. 8 Potential for mutagenesis was measured with assays for variable, diverse, and joining (VDJ) immunoglobulin receptor rearrangement, fl ow cytometric quantifi cation of young reticulocyte micro nuclei, and chromosome and chromatid breaks. 13, 14 Infants were monitored every 2 weeks for adverse events and laboratory toxic eff ects until a tolerable dose was confi rmed, and then every 4 weeks. 8 Adverse clinical events included known complications of sickle-cell anaemia, such as pain, dactylitis, acute chest syndrome, stroke, priapism, sepsis or bacteraemia, splenic sequestration, hospitalisation, and transfusion.
Serious adverse events were reviewed by an independent classifi cation committee (panel 1 shows defi nitions).
Statistical analysis
All patients randomly assigned to a treatment group were analysed for the coprimary endpoints. Methodology for the collection and analysis of study endpoint data has been published previously. 8 Data analysis was done with the statistical package SAS (version 9.2). The α level for the coprimary endpoints was divided disproportionately, with 0·04 allocated to the spleen and 0·01 to the renal endpoint. A sample size of 100 patients per group provided greater than 95% power to detect an estimated proportion with worsening spleen function of 0·6 in the control group versus 0·3 in the hydroxycarbamide group, assuming a two-sided type I error rate of 4%, and to detect a 60% diff erence in the exit versus baseline GFR measurements in the two groups, allowing a two-sided type I error rate of 1%. A group sequential design was used to adjust for 6-month interim-analysis reviews done by an independent data safety and monitoring board. Interim boundaries were widely set to enable the most powerful comparison to be done at the end of the study, should an interim boundary not be crossed during the trial. For secondary endpoints, a p value of 0·01 or less was considered signifi cant. Continuous variables are presented as means with SDs, and compared with the two-sample Student's t test. Categorical variables are presented as proportions, and compared with the Pearson χ² or Fisher's exact test. All adverse events were treated as either time to fi rst event or a counting process event variable, and analysed with the log-rank life test or the counting process approach of Anderson and Gill. 15 Effi cacy analyses were adjusted for baseline measurements. The generalised estimating equation method was used for analysing correlated or serially gathered data, and multiple imputation was used to adjust for missing data.
The trial is registered with ClinicalTrials.gov, number NCT00006400.
Role of the funding source
The NHLBI provided an initial draft of the study design. The study sponsors did not collect, analyse, report, or interpret data. Two employees of the NHLBI (JCG, MAW) contributed to the writing of the manuscript. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
193 infants with HbSS (n=187) or Sβ⁰thalassaemia (n=6), mean age 13·6 months (range 9-18), were randomly assigned to a treatment group at 13 clinical centres (fi gure 1). A temporary administrative clinical hold on all study activity occurred from March to June, 2006, because of a specifi ed expiration date on one lot of treatment bottles. 179 (93%) participants who completed at least 18 months of the trial and at least one exit assessment were analysed; 167 (86%) completed the full study. 96 children were randomly assigned to hydroxycarbamide, and 97 to placebo, with no signifi cant diff erences in age, sex, genotype, clinical severity of sickle-cell anaemia, laboratory values, or physical fi ndings (table 1) .
We recorded no signifi cant diff erence between hydroxycarbamide and placebo groups for either of the primary endpoints (table 2, table 3 ). Qualitative spleen scans were worse at exit than at entry in 19/70 (27%) of those on hydroxycarbamide and 28/74 (38%) of those receiving placebo (diff erence 11%, 95% CI -26 to 5, p=0·21). GFR, measured by ⁹⁹ m Tc-DTPA clearance, did not diff er in the two groups (diff erence 2 mL/min per 1·73m², -16 to 20, p=0·84).
Quantitative measures of spleen function (Howell-Jolly bodies, pit counts, and ratio of spleen to liver count) suggested benefi t from hydroxycarbamide when we compared exit versus entry diff erences between the hydroxycarbamide and placebo groups (table 4). By 1-3 months after starting study drug, blood counts diff ered in the hydroxycarbamide and placebo groups (fi gure 2, table 5). Haemoglobin and fetal haemoglobin concentrations were relatively stable in the hydroxycarbamide group between entry and exit, whereas normal age-related declines occurred in the placebo group. Infants in the hydroxycarbamide group had higher mean exit concentrations of haemoglobin (by 5 g/L), fetal haemoglobin (by 5·3%), and mean corpuscular volume (by 6·0 fL), and lower white blood cell, neutrophil, and absolute reticulocyte counts than did those in the placebo group (fi gure 2, table 5). Exit versus entry diff erences between the groups were signifi cant (table 5) .
Exit versus entry diff erences in the hydroxycarbamide group also showed a trend towards higher urine osmolality and specifi c gravity, and lower total kidney volume compared with those in the placebo group. The increase in time-averaged mean maximum TCD velocity from baseline to exit was lower in the hydroxycarbamide group than in the placebo group (20 cm/s vs 32 cm/s). We recorded no diff erences between groups in the average Bayley MDI or Vineland scores for communication, daily living skills, socialisation, and motor skills (data not shown), although all fi ve participants with an MDI less than 70 at exit had received placebo. Growth was not aff ected by hydroxycarbamide.
Acute event rates for the most common complications of sickle-cell anaemia diff ered substantially in the two groups (table 6) . Pain was nearly twice as frequent and dactylitis fi ve times more common in the placebo group. Acute chest syndrome was three times higher in the placebo group than in the hydroxycarbamide group. Hospitalisations and transfusions were marginally more common in the placebo group (table 6); most hospitalisations occurred for reasons other than pain (usually fever). Diff erences between the two groups were apparent by about 50 days (dactylitis), 100 days (pain), and 300 days (acute chest syndrome and transfusion) after treatment initiation (fi gure 3). Sepsis or bacteraemia occurred in two patients in the hydroxycarbamide group and in fi ve in the placebo group.
Episodes of splenic sequestration were equal in the two groups. Gastroenteritis occurred less frequently in those receiving hydroxycarbamide.
The only frequent toxicity, mild-to-moderate neutropenia (absolute neutrophil count 500-1249/μL³), occurred 107 times in 45 participants in the hydroxycarbamide group and 34 times in 18 participants in the placebo group (table 7) . Recurrent or persistent neutropenia resulted in nine long-term dose decreases (to 17·5 mg/kg per day) in the hydroxycarbamide group and fi ve in the placebo group (p=0·20). More severe neutropenia (absolute neutrophil count <500/μL³) was rare and not associated with invasive The cumulative probability curves were generated by the time to fi rst event for acute chest syndrome (A), pain (B), dactylitis (C), and transfusion (D). The diff erences in the events between the treatment groups were assessed with the log-rank life test. The p values for cumulative probability curves were 0·02 for acute chest syndrome, 0·002 for pain, <0·0001 for dactylitis, and 0·03 for transfusion. infection. Thrombocytopenia and reticulocytopenia were similar in the two groups. At study exit, chromosome and chromatid breaks did not diff er in the two groups when compared with baseline levels, nor did we record any diff erences in VDJ recombination events or micronuclei assay results (data not shown).
Patients at risk
Discussion
Hydroxycarbamide was safe and resulted in a decrease in common but serious adverse events, especially pain and dactylitis, as well as improved laboratory parameters. Several secondary measures of spleen, kidney, and CNS function suggested benefi t, but these results were not conclusive.
BABY HUG is, to our knowledge, the fi rst randomised, double-blind trial of hydroxycarbamide in children with sickle-cell anaemia (panel 2). It diff ers from all other paediatric trials (except for the pilot HUSOFT study) in that the participants were much younger at enrolment (mean age 13·6 months), and a severe clinical course (eg, three or more vaso-occlusive events in the previous year) was not a prerequisite for entry. No previous systematic reviews or meta-analyses of the eff ects of hydroxy carbamide on splenic or renal function in sickle-cell anaemia have been published. In our literature review we found two retrospective studies that showed modest preservation of splenic uptake in older children, 19, 20 and a small prospective study that showed no eff ect. 21 Published data for the eff ects of hydroxycarbamide on renal function report possible eff ects on proteinuria and micro albuminuria. 22, 23 One study found that GFR did not increase after 2 years of hydroxy carbamide treatment in preschool-aged children. 23 Hydroxyurea did not prevent a reduction in splenic function assessed by qualitative spleen scan uptake. However, compared with previous reports, the decline in function on spleen scan occurred in a smaller than expected proportion in the placebo group (38%), and in an even smaller (but not signifi cantly diff erent) proportion (27%) of those treated with hydroxycarbamide. Because serum creatinine concentrations, often used to estimate glomerular function, are diminished in individuals with sickle-cell anaemia, we used ⁹⁹ m Tc-DTPA clearance, which is a more defi nitive assessment of GFR that does not require urine collection. As expected, increased GFR for age was present at baseline, 7, 10 and further increases were seen at exit, but hydroxycarbamide had no eff ect on glomerular hyperfi ltration.
Possible explanations for the lack of diff erence between the hydroxycarbamide and placebo groups in terms of primary endpoints include: use of a fi xed dose of hydroxycarbamide (20 mg/kg per day), which is lower than the usual maximum tolerated dose and perhaps clinically less eff ective; 3,24 the relatively short duration of the trial (perhaps with further compromise by the 3-month clinical hold), which could have been insuffi cient to see changes; the small number of participants; and suboptimum endpoint measurements, which might not have been sensitive enough to detect subtle changes in splenic and renal function. Unfortunately, at entry nearly three-quarters of participants were classifi ed as the intermediate category of decreased but not absent splenic uptake on qualitative spleen scan; changes within this category could not be taken into account when analysing the primary endpoint. Of course, hydroxycarbamide might not prevent organ dysfunction in infants, or it might off er only some protection. An open-label follow-up study of this cohort that allows dose escalation is underway (NCT00890396). Of the 179 patients who completed at least 18 months of follow up in the BABY HUG trial, 163 (91%) are enrolled in the follow-up study. For 133 (82%) of these patients, their families have chosen to use open-label hydroxycarbamide, usually with an escalation to the maximum tolerated dose.
Three secondary measures of splenic function (liver count ratios, pit counts, and Howell-Jolly bodies) suggested benefi t from hydroxycarbamide when adjusted for baseline values; the potential use of baseline pit counts and Howell-Jolly bodies from the BABY HUG study has been analysed. 11 Two secondary measures of renal function (urine osmolality and specifi c gravity) suggested benefi t from hydroxycarbamide. The greater total kidney volume on ultrasonography in the placebo group might indicate nephromegaly due to hyperfi ltration. Moreover, hydroxycarbamide might favourably aff ect CNS pathology, which is a major problem in older children with sickle-cell anaemia. The average increase in TCD velocity, an established indicator of stroke risk in older children, was signifi cantly less in those receiving hydroxycarbamide than in those receiving placebo, probably indicating the higher mean haemoglobin concentration in that group. Although the mean MDI was similar in the two groups, all fi ve participants with scores lower than 70 at exit had received placebo. Most importantly, participants in the hydroxycarbamide group had substantial clinical benefi t, including lower rates of pain and dactylitis, and decreases in the occurrence of acute chest syndrome, admission to hospital, and transfusion, in addition to improved haematological parameters. Proportionally, the decreases in pain, acute chest syndrome, admission to hospital, and transfusion seen in our unselected patients were very similar to those recorded in severely aff ected adults in the MSH trial, 4 which led the US Food and Drug Administration to approve hydroxycarbamide for adults with severe sickle-cell anaemia.
The reduction in clinical events and improved haematological parameters with hydroxycarbamide should improve long-term prognosis. Recurrent pain and acute chest syndrome and higher white blood cell counts were associated with early mortality in the CSSCD trial. 2 Haemoglobin concentrations lower than 70 g/L, increased white blood cell count during the second year of life, and dactylitis before age 1 year were associated with increased risk for severe outcomes later in life, 25 although these fi ndings were not replicated in a more recent newborn cohort. 26 Higher haemoglobin concentrations, lower reticulocyte counts, and lower bilirubin concentrations in the BABY HUG hydroxycarbamide group indicate reduced haemolysis, which should diminish nitric oxide depletion and its deleterious vascular eff ects.
The only toxic eff ect we detected from hydroxycarbamide in this infant cohort was mild-to-moderate neutropenia, but we detected no signifi cant diff erences in severe neutropenia or in the number of bacteraemia or sepsis events between the hydroxycarbamide and placebo groups. Despite some previous concerns, 17 hydroxycarbamide did not increase the frequency of splenic sequestration or have any detrimental eff ects on growth or neurodevelopment. With several assays for mutagenesis, no signifi cant diff erences between the hydroxycarbamide and placebo groups were noted. Long-term follow-up of participants with sickle-cell anaemia, averaging 17·5 years for those in the MSH study, 27 8 years for an adult Greek cohort, 28 12 years (to date) for the HUSOFT participants, 29 and 8 years for the Duke paediatric cohort, 24 has not shown any unexpected toxic eff ects from hydroxycarbamide. In fact, extended use has probably improved survival in adults. 27, 28 However, because the risk of neoplasia is unknown when hydroxycarbamide is begun early in life, long-term follow-up is crucial.
A National Institutes of Health Consensus Conference concluded that hydroxycarbamide is underused in adults with sickle-cell anaemia. 30 The laboratory and clinical benefi ts of hydroxycarbamide for children and adolescents with sickle-cell anaemia, coupled with an excellent short-term and long-term safety profi le, suggest that hydroxycarbamide is also underused in young patients. Further follow-up of the BABY HUG cohort is now planned until 2016, when participants will be 9-13 years of age, and will provide valuable data for longer-term benefi cial and toxic eff ects.
In conclusion, we believe that the results of the BABY HUG study should have a major eff ect on guidelines for the management of children with sickle-cell anaemia. On the basis of the safety and effi cacy data from this trial, hydroxycarbamide therapy can now be considered for all very young children with sickle-cell anaemia whether or not they have clinical symptoms. Future monitoring of this approach should be improved by a sickle cell registry in the USA and a global sickle disease network.
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